Keynote Session: CAR T-cell Therapy - Focus on Lymphomas
Chimeric antigen receptor (CAR) T-cell therapy is a new and rapidly evolving immunotherapy emerging as a novel treatment option for relapsed or refractory lymphomas.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Keynote Session: CAR T-cell Therapy - Historical Perspectives and Major Milestones
Chimeric antigen receptor (CAR) T-cell therapy is an immune-based therapy used in cancer treatment that has demonstrated efficacy in the management of many hematologic malignancies, suggesting significant impact on oncology practice.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing the Care of Patients Receiving CAR T-Cell Therapy
Patients with relapsed or refractory hematologic disorders like acute lymphoblastic leukemia and diffuse large B-cell lymphoma have poor outcomes and require novel effective therapies.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Patient Case Studies and Panel Discussion: Lymphoma
Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation